We provide you with 20 years of free, institutional-grade data for FHTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FHTX. Explore the full financial landscape of FHTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Foghorn Therapeutics Inc(NASDAQ:FHTX) 
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug tar...
Website: http://www.foghorntx.com
Founded: 2015
CEO: Adrian Gottschalk
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about FHTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.